ATE195553T1 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
ATE195553T1
ATE195553T1 AT93915279T AT93915279T ATE195553T1 AT E195553 T1 ATE195553 T1 AT E195553T1 AT 93915279 T AT93915279 T AT 93915279T AT 93915279 T AT93915279 T AT 93915279T AT E195553 T1 ATE195553 T1 AT E195553T1
Authority
AT
Austria
Prior art keywords
csf
antagonists
directed
agonists
crystallization
Prior art date
Application number
AT93915279T
Other languages
English (en)
Inventor
Jayvardhan Pandit
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Robert Halenbeck
Anna Lisa Fear
Eric Taylor
Ralph Yamamoto
Andrew Bohm
Original Assignee
Chiron Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ California filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE195553T1 publication Critical patent/ATE195553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93915279T 1992-06-09 1993-06-09 Kristallisierung von m-csf ATE195553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (1)

Publication Number Publication Date
ATE195553T1 true ATE195553T1 (de) 2000-09-15

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915279T ATE195553T1 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (de)
EP (2) EP0955365A3 (de)
JP (2) JPH08507916A (de)
AT (1) ATE195553T1 (de)
CA (1) CA2137793C (de)
DE (1) DE69329247T2 (de)
WO (1) WO1993025687A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
EP1425304B9 (de) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf konjugate
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
WO2006047505A2 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Crystal structure of the c-fms kinase domain
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
WO2010062401A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
BR112012013717B1 (pt) 2009-12-10 2020-01-28 Hoffmann La Roche anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
WO2013036829A1 (en) 2011-09-09 2013-03-14 Genentech, Inc Treatment of th17 mediated inflammatory diseases
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR20230086809A (ko) 2014-06-23 2023-06-15 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
BR112017008914A2 (pt) 2014-10-29 2018-01-16 Five Prime Therapeutics, Inc. método para tratar câncer, composição e uso da composição
CA2969341C (en) 2014-12-22 2023-07-04 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
MX2017013178A (es) 2015-04-13 2018-03-01 Five Prime Therapeutics Inc Terapia de combinacion para cancer.
EP3504239B1 (de) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intervalldosierung eines anti-csf-1r-antikörpers in kombination mit makrophagenaktivierungsmittel
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
EP3681535A1 (de) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Kombination von anti-csf1r und anti-pd-1-antikörperkombinationstherapie beibauchspeicheldrüsenkrebs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
JP2975109B2 (ja) * 1989-12-21 1999-11-10 ノボ ノルディスク アクティーゼルスカブ 酵素の結晶化方法
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists

Also Published As

Publication number Publication date
US6184354B1 (en) 2001-02-06
EP0668914B1 (de) 2000-08-16
CA2137793C (en) 2003-04-22
WO1993025687A1 (en) 1993-12-23
EP0955365A3 (de) 2000-12-20
JPH08507916A (ja) 1996-08-27
EP0955365A2 (de) 1999-11-10
DE69329247D1 (de) 2000-09-21
US5866114A (en) 1999-02-02
JP2004285076A (ja) 2004-10-14
DE69329247T2 (de) 2001-05-31
EP0668914A1 (de) 1995-08-30
CA2137793A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
ATE195553T1 (de) Kristallisierung von m-csf
ES2113368T3 (es) Antagonistas de serotonina.
IT1217328B (it) Processo per la metallizzazione di materiali fibrosi
ES2135477T3 (es) Proceso de produccion de (s)-3-amino-1-pirrolidinas sustituidas.
DK0444853T3 (da) Hexahydrobenz(cd)indoler
ES2067541T3 (es) Mejoras en antagonistas de la serotonina y relacionadas con ellos.
ATE69220T1 (de) Sechsgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
ATE63543T1 (de) 2-oxindolzwischenprodukte.
ES533939A0 (es) Un procedimiento de preparacion de nuevos derivados de 4-aminopiperidina
EP0480764A3 (en) Process to find stability of oil mixtures, including shale oil and fractions thereof
DE3876193D1 (de) Aminomethylderivate von mono- und dithiocarbamaten als schmiermitteladditive.
KR950700899A (ko) 히스타민 수용체 길항물질의 합성에 있어서 중간물질로써 유용한 4-피리딜과 4 피페리디닐아미다졸의 제조공정
IT1174473B (it) Procedimento per la produzione di polietelene di bassa densita'lineare
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
DE69019301T2 (de) Herstellungsverfahren von Indolen.
PT90719A (pt) Processo de preparacao de 2-etenil-3,4,5,6-tetra-hidrotieno{4,3,2-ef}{3} benzazepinas substituidas e de composicoes farmaceuticas que as contem
CA1262906C (en) 3-(2-FUROYL)-5-ALCOXYCARBONYL-2,6-DIMETHYL-4-(2-NITROPHENYL)-1,4-DIHYDROPYRIDINES, CALCIUM ANTAGONISTS
NO891681D0 (no) Fremgangsmaate for syntese av c5+ hydrokarboner.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
IT8719647A0 (it) Processo per la sintesi dell'epsiloncaprolattame.
FR2640414B1 (fr) Electro-aimant de coupure alimente en courant alternatif
IT1229214B (it) Processo per la sintesi della n metil 3,4 dimetossifeniletilamina
IT1226147B (it) Processo per la preparazione di perfluoro (2 bromoetilviniletere).
BR8905403A (pt) Processo para sintetizar n,n'-ditiobis (sulfonamidas)
FI873000A (fi) Substituoituja 1,2,3-tiadiatsoli-4-tiolaatteja

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties